CATALIS’ Management Being Supported by Two New Advisory Committees
Until recently, CATALIS’ management has been guided by three main advisory committees: a patient advisory committee made up of fifteen patient and patient-partner associations, a scientific and innovation advisory committee made up of expert clinical researchers, and an operations advisory committee made up of senior representatives from health institutions, pharmaceutical companies, and government representatives which focuses on the recommendations of some thirty highly specialized and qualified contract management and research ethics experts.
Committed to having a comprehensive understanding of Quebec’s clinical research environment and listening to its Network of partners, CATALIS Quebec’s executives recently created two new advisory committees to oversee the strategic alignment of its operations.
The data, artificial intelligence, and real-world evidence advisory committee
In keeping with the government’s desire to modernize access to data, CATALIS recently created a new advisory committee on data, artificial intelligence, and real-world evidence. This new committee’s mandate is to identify the main issues and prioritize the needs of non-academic researchers for accessing and using clinical-administrative data from health network institutions for clinical research purposes. As such, nearly twenty provincial and international experts recently joined CATALIS’ brainstorming and have submitted a brief to support the Quebec government’s towards Bill 3.
The research pharmacy advisory committee
In addition to the operations, scientific, innovation, and patient advisory committees, CATALIS recently created a new advisory committee specific to research pharmacies in Quebec’s health network institutions. The purpose of this committee is to identify pharmacies’ operational issues within the clinical research context to develop innovative provincial solutions to facilitate and accelerate administrative processes related to the evaluation and conduct of clinical trials, including better adaptation to decentralized clinical trials.
CATALIS takes this opportunity to acknowledge the work and commitment of the CATALIS Network’s partners, which include more than 120 specialized public-private experts who contribute to the success of CATALIS’ government mandate.
